This paper discusses an essential interdisciplinary issue, pelvic congestion syndrome (PGS). PGS is a venous disorder with gonadal vein and/or pelvic venous plexus dilation that results in pelvic venous plethora. The authors address PGS prevalence, causes, underlying pathophysiological mechanisms, major clinical manifestations, diagnostic tools, and treatment approaches. Pharmacotherapy (gonadotropin-releasing hormone agonists, danazol, combined oral contraceptives, progestins, phlebotonics, etc.) is the first-line treatment that provides only a temporary effect. Image-guided vascular surgery (embolization, stenting) is of particular importance among surgical interventions. Surgical technique and critical results of the studies on the efficacy of gonadal vein embolization (from 47% to 100%) are described. The paper details major complications of surgical interventions and highlights issues requiring further researches, i.e., the effects on female fertility, predicted full recovery considering compromised somatic and/or gynecological anamnesis. Finally, the importance of timely diagnosis, greater awareness of primary care physicians on the signs and symptoms of this disorder, and a need to refer these women to vascular surgeons are addressed. KEYWORDS: pelvic congestion syndrome, gonadal vein embolization, pelvic pain, May–Thurner syndrome, nutcracker syndrome. FOR CITATION: Antropova E.Yu., Sharafutdinov B.M., Mazitova M.I. et al. Pelvic congestion syndrome is an interdisciplinary issue. Russian Journal of Woman and Child Health. 2021;4(4):346–350 (in Russ.). DOI: 10.32364/2618-8430-2021-4-4-346-350.
Congenital anomalies of the urogenital system constitute approximately 20 to 30% of all birth defects. Renal dystopia means a congenital abnormal location of one or both kidneys. The authors present a clinical case report, demonstrating the efficacy of uterine artery embolization as an alternative method of treatment for patients with uterine fibroids and renal dystopia. Uterine artery embolization is not only an organ- preserving treatment option for women who wish to retain the reproductive organ but also offers a clear visualization of the individual anatomical variations. Taking into consideration a strong patient’s wish to preserve the uterus and her individual vascular anomalies (absence of the left uterine and renal arteries), uterine artery embolization was an alternative treatment option which enabled to preserve both the uterus and the left kidney. The scheduled examination findings demonstrated a 1.87-fold reduction of the uterine volume and a 12.8-fold reduction of the fibroid size from baseline, and color doppler ultrasonography revealed that the uterine fibroid was avascular. For patients with diagnosed congenital anomalies of the urogenital system, the authors recommend using computer tomography and referrals to interdisciplinary specialists for choosing the appropriate uterine fibroid treatment options KEYWORDS: uterine fibroids, pelvic kidney dystopia, uterine artery embolization, organ-preserving treatment methods, congenital anomalies of the urogenital system, computer tomography. FOR CITATION: Antropova E.Yu., Sharafutdinov B.M., Mazitova M.I. et al. Organ-preserving approach to the treatment of patients with uterine fibroids and congenital anomaly of the urinary system (a clinical case). Russian Journal of Woman and Child Health. 2022;5(4):320–325 (in Russ.). DOI: 10.32364/2618-8430-2022-5-4-320-325.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.